Provider Workforce Assessment in a Rural Hepatitis C Epidemic:Implications for Scale-up of Antiviral Therapy

Journal of Primary Care & Community Health

Volumn 6, Issue 3, 2015, Pages 215-217

  Westergaard, Ryan P ^a   Stockman, Lauren J ^b   Hyland, Heather A ^c   Guilfoyle, Sheila M ^b   Fangman, John J ^c   Vergeront, James M ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WISCONSIN DIVISION OF PUBLIC HEALTH   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

access to care; efficiency; medications; primary care; rural health

Indexed keywords

ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; TELAPREVIR;

ANALOGS AND DERIVATIVES; CLINICAL PRACTICE; EPIDEMIOLOGY; HEALTH; HEALTH CARE DELIVERY; HEPATITIS C; HUMAN; PRIMARY HEALTH CARE; RURAL HEALTH CARE; STATISTICS AND NUMERICAL DATA; WISCONSIN;

ANTIVIRAL AGENTS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; OLIGOPEPTIDES; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; PROLINE; RURAL HEALTH; RURAL HEALTH SERVICES; WISCONSIN;

EID: 84990358791     PISSN: 21501319     EISSN: 21501327     Source Type: Journal    
DOI: 10.1177/2150131914560229     Document Type: Article

References (12)

1. Fried MW Shiffman ML Reddy KR. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
2. Afdhal N Reddy KR Nelson DR; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-1493.
3. Smith BD Morgan RL Beckett GA. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
4. Moyer VA, US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Sep 3 2013;159(5):349-357.
5. Liang TJ Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907-1917.
6. Centers for Disease Control and Prevention. Notes from the field: hepatitis C virus infections among young adults’rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(19):358.
7. Wisconsin Department of Health Services. Epidemiologic profile of hepatitis C virus (HCV) in Wisconsin. http://www.dhs.wisconsin.gov/publications/P0/p00860.pdf. Accessed September 29,2014.
8. Morrill JA Shrestha M Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754-758.
9. McGowan CE Monis A Bacon BR. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57:1325-1332.
10. Arora S Thornton K Murata G. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-2207.
11. Fathauer L Meek J. Initial implementation and evaluation of a hepatitis C treatment clinical decision support system (CDSS): a nurse practitioner-driven quality improvement initiative. Appl Clin Inform. 2012;3:337-348.
12. Afdhal NH Zeuzem S Schooley RT. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20:745-760.